Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

NCT02796170 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Hypertension

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

Tulane University School of Medicine

Collaborators

[object Object]